Munich has long been recognized as one of Germany’s scientific powerhouses, but in recent years it has also emerged as one of Europe’s most dynamic biotech and life sciences ecosystems. Bringing ...

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

Europe’s pandemic preparedness capital is creating a rare opening for biotech innovators. Since COVID-19, the next pandemic is no longer abstract, and preparedness is no longer optional. Europe is ...

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

Novartis’ current strategy can be traced back to October 2023, when the Swiss pharma completed the spin-off of Sandoz, its generics and biosimilars business. The company described the move as the ...

Artificial intelligence (AI) may be transforming drug discovery, but one of the industry’s biggest problems remains unchanged: much of the biology used to develop new medicines still does not fully ...

So far, the visible strategy around bronchiectasis has been managing the problems it creates — mucus retention, repeated infections, airway inflammation, and exacerbations. Airway clearance, ...

In vivo CAR-T therapies have grown in demand over the years, as scientists have figured out how to crack the challenges of target specificity and safety, proving to be more efficient than ex vivo ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

Life science companies regularly forge mergers and acquisition (M&A) deals to eliminate competition or to expand a pipeline. Recently, there has been a spike in M&As, but analysts point towards ...